Cargando…
Cellular and Biophysical Pipeline for the Screening of Peroxisome Proliferator-Activated Receptor Beta/Delta Agonists: Avoiding False Positives
Peroxisome proliferator-activated receptor beta/delta (PPARß/δ) is considered a therapeutic target for metabolic disorders, cancer, and cardiovascular diseases. Here, we developed one pipeline for the screening of PPARß/δ agonists, which reduces the cost, time, and false-positive hits. The first ste...
Autores principales: | Videira, Natália Bernardi, Batista, Fernanda Aparecida Heleno, Torres Cordeiro, Artur, Figueira, Ana Carolina Migliorini |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Hindawi
2018
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5924986/ https://www.ncbi.nlm.nih.gov/pubmed/29849537 http://dx.doi.org/10.1155/2018/3681590 |
Ejemplares similares
-
Structural Insights into Human Peroxisome Proliferator Activated Receptor Delta (PPAR-Delta) Selective Ligand Binding
por: Batista, Fernanda A. H., et al.
Publicado: (2012) -
Peroxisome Proliferator-Activated Receptor Beta/Delta Agonist Suppresses Inflammation and Promotes Neovascularization
por: Tobita, Yutaro, et al.
Publicado: (2020) -
Screening for PPAR Non-Agonist Ligands Followed by Characterization of a Hit, AM-879, with Additional No-Adipogenic and cdk5-Mediated Phosphorylation Inhibition Properties
por: Ribeiro Filho, Helder Veras, et al.
Publicado: (2018) -
Gene Doping with Peroxisome-Proliferator-Activated Receptor Beta/Delta Agonists Alters Immunity but Exercise Training Mitigates the Detection of Effects in Blood Samples
por: Sibille, Brigitte, et al.
Publicado: (2021) -
Avoiding false discovery in biomarker research
por: Patel, Pranali, et al.
Publicado: (2016)